BML-284 (Wnt agonist 1)是一种Wnt信号通路的强效激动剂，诱导β-catenin和TCF依赖性转录活性的EC50值为0.7μM。
Cas No.:853220-52-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BML-284 (Wnt agonist 1) is a potent agonist of Wnt signaling, with an EC50 value of 0.7μM for inducing β-catenin- and TCF-dependent transcriptional activity[1]. BML-284 binds to the colchicine-site and forms a low barrier hydrogen bond with E198 of β-tubulin, to mediate αβ-tubulin degradation through the ubiquitin-proteasome pathway[2]. BML-284 has been widely used as a model compound to synthesize a series of photosensitive azo derivatives that undergo reversible cis-trans isomerization upon visible light irradiation, with the cis-isomer capable of activating Wnt signaling [3].
In vitro, BML-284 treatment for 72 hours significantly inhibited the proliferation of HeLa, HCT116, MCF-7 and K562 cells with IC50 values of 0.09µM, 0.52µM, 0.69µM and 0.10µM, respectively[4]. Treatment with 1µM BML-284 for 24 hours promoted invasion and inhibited apoptosis of A549 cells transfected with pcDNA-AOC4P[5]. Pre-incubation of human aortic vascular smooth muscle cells (HA-VSMCs) with 10µM BML-284 for 24 hours activated the Wnt signaling pathway, increased the protein expression of Wnt3a and β-catenin, and reversed the protective effects of si-SOX2 on calcification, osteogenic/contractile protein expression, and autophagy activity[6].
In vivo, BML-284 treatment (5μl; 0.5μg/eye) via injection into the conjunctiva adjacent to the limbus for 48 hours promoted corneal epithelial healing and corneal nerve repair in diabetic mice[7]. BML-284 treatment via daily intravenous injection at a dose of 500µl (2mg/ml) for 14 days antagonized the protective effect of Triptolide (TP) against myocardial fibrosis (MF) by activating the Wnt/β-catenin pathway, and aggravated cardiac dysfunction in rats[8].
References:
[1] Liu J, Wu X, Mitchell B, et al. A small‐molecule agonist of the Wnt signaling pathway[J]. Angewandte Chemie International Edition, 2005, 44(13): 1987-1990.
[2] Yang J, Li Y, Qiu Q, et al. Small molecules promote selective denaturation and degradation of tubulin heterodimers through a low-barrier hydrogen bond[J]. Journal of Medicinal Chemistry, 2022, 65(13): 9159-9173.
[3] Ahmad S, Hashim P K, Imajo M, et al. Photoswitchable agonists for visible-light activation of the Wnt signaling pathway[J]. Organic & Biomolecular Chemistry, 2025, 23(17): 4240-4245.
[4] Zhang C, Yan W, Liu Y, et al. Structure-based design and synthesis of BML284 derivatives: A novel class of colchicine-site noncovalent tubulin degradation agents[J]. European Journal of Medicinal Chemistry, 2024, 268: 116265.
[5] Li F, Rong T, Cao G, et al. AOC4P suppresses viability and invasion and induces apoptosis in NSCLC cells by inhibiting the Wnt/β-catenin pathway[J]. Chemico-Biological Interactions, 2020, 325: 109110.
[6] Xiang H, Hong J, Zhang Y, et al. Inhibition of SOX2 mitigates vascular calcification mediated by autophagy through Wnt signaling pathway[J]. Egyptian Journal of Medical Human Genetics, 2025, 26(1): 189.
[7] Yang S, Zhang Y, Zhang Z, et al. Insulin promotes corneal nerve repair and wound healing in type 1 diabetic mice by enhancing Wnt/β-catenin signaling[J]. The American Journal of Pathology, 2020, 190(11): 2237-2250.
[8] Zhang Y, Lu F. Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway[J]. Scandinavian Cardiovascular Journal, 2024, 58(1): 2295785.
BML-284 (Wnt agonist 1)是一种Wnt信号通路的强效激动剂，诱导β-catenin和TCF依赖性转录活性的EC50值为0.7μM[1]。BML-284结合在秋水仙碱位点，并与β-微管蛋白的E198形成低能氢键，从而通过泛素-蛋白酶体途径介导αβ-微管蛋白降解[2]。BML-284已广泛用作模型化合物，用于合成一系列在可见光照射下可发生可逆顺反异构化的光敏偶氮衍生物，其中顺式异构体能够激活Wnt信号通路[3]。
在体外，BML-284处理72小时显著抑制了HeLa、HCT116、MCF-7和K562细胞的增殖，IC50值分别为0.09µM、0.52µM、0.69µM和0.10µM[4]。用1µM的BML-284处理24小时促进了转染pcDNA-AOC4P的A549细胞的侵袭并抑制了细胞凋亡[5]。用10µM的BML-284预孵育人主动脉血管平滑肌细胞（HA-VSMCs）24小时激活了Wnt信号通路，增加了Wnt3a和β-catenin的蛋白表达，并逆转了si-SOX2对钙化、成骨/收缩蛋白表达和自噬活性的保护作用[6]。
在体内，向角膜缘附近的结膜注射BML-284（5μl；0.5μg/眼）处理48小时促进了糖尿病小鼠的角膜上皮愈合和角膜神经修复[7]。每日静脉注射500µl（2mg/ml）剂量的BML-284连续14天，通过激活Wnt/β-catenin通路拮抗了Triptolide（TP）对心肌纤维化（MF）的保护作用，并加重了大鼠的心脏功能障碍[8]。
| Cell experiment [1]: | |
Cell lines | HeLa cells |
Preparation Method | HeLa cells were seeded in 96-well plates at a density of 5000 cells/well and kept in an incubator with 5% CO2 at 37°C overnight. Subsequently, the cells were treated with the BML-284 at the indicated concentrations (0.001, 0.01, 0.1, 1, and 10µM) for 72h. Paclitaxel was used as the positive control. MTT powder was dissolved in physiological saline to obtain a 5mg/ml solution; then, 20μl MTT solution was added to each well and incubated at 37°C for 2h. The absorbance of each well was determined at 570nm. |
Reaction Conditions | 0.001, 0.01, 0.1, 1, and 10µM; 72h |
Applications | BML-284 treatment inhibited the cell viability of HeLa cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Seventy-two male Sprague-Dawley rats (8 weeks of age, 220±20g) were housed individually in cages maintained at 23±1°C with a 12-h light/dark cycle and ad libitum access to food and water. After 1 week of acclimatization, isoproterenol (ISO) was dissolved in normal saline and injected subcutaneously into the rats at a dose of 5mg/kg/day for 14 consecutive days to establish a rat model of myocardial fibrosis (MF). Rats were randomly divided into four groups: normal control group (NC group), ISO group, TP+ISO group, and BML-284+TP+ISO group. Rats in the ISO, TP+ISO, and BML-284+TP+ISO groups were injected subcutaneously with ISO (5mg/kg/day), and rats in the NC group were injected subcutaneously with the same volume of normal saline. Rats in TP+ISO group were injected subcutaneously with TP at a concentration of 150μg/kg. In the BML-284+TP+ISO group of rats, a daily intravenous injection of 500µl of BML-284 (2mg/ml) was administered, along with subcutaneous injections of TP (μg/kg) and ISO (5mg/kg) over a period of 14 days. Rat hearts were removed for analysis. |
Dosage form | 500µl (2mg/ml); once a day for 14 days; i.v. |
Applications | BML-284 antagonized the protective effect of TP against MF by activating the Wnt/β-catenin pathway and aggravated cardiac dysfunction in rats. |
References: | |
| Cas No. | 853220-52-7 | SDF | |
| 别名 | WNTAGONIST1(CID11210285盐酸盐),BML-284 | ||
| 化学名 | (Z)-1-(benzo[d][1,3]dioxol-5-yl)-N-(2-imino-6-(3-methoxyphenyl)-2,3-dihydropyrimidin-4(1H)-ylidene)methanamine hydrochloride | ||
| Canonical SMILES | COC1=CC=CC(C(NC2=N)=C/C(N2)=N/CC3=CC4=C(OCO4)C=C3)=C1.Cl | ||
| 分子式 | C19H19ClN4O3 | 分子量 | 386.83 |
| 溶解度 | ≥ 38.7mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5851 mL | 12.9256 mL | 25.8511 mL |
| 5 mM | 517 μL | 2.5851 mL | 5.1702 mL |
| 10 mM | 258.5 μL | 1.2926 mL | 2.5851 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet